Skip to main content

Table 1 Baseline clinical characteristics

From: Clinical value of drug-coated balloon versus second-generation drug-eluting stent for de novo lesions in large coronary arteries: insights from the real world

 

Before propensity matching

 

After propensity matching

DCB

sDES

P-value

 

sDES

P-value

Number of patients

708

2149

  

704

 

Age [(years), median (IQR)]

56(48,65)

56(50,64)

0.109

 

57(51,64)

0.066

Age>65 years, n (%)

185(26.1%)

510(23.7%)

0.197

 

177(25.1%)

0.671

Male, n (%)

568(80.2%)

1563(72.7%)

<0.001

 

561(79.7%)

0.800

CAD diagnosis

      

 ACS

662(93.5%)

2022(94.1%)

0.570

 

664(94.3%)

0.522

  UA, n (%)

499(70.5%)

1513(70.4%)

0.970

 

478(67.9%)

0.293

  NSTEMI, n (%)

121(17.1%)

407(18.9%)

0.272

 

141(20.0%)

0.156

  STEMI, n (%)

42(5.9%)

102(4.8%)

0.211

 

45(6.4%)

0.719

 SCAD, n (%)

46(6.5%)

127(5.9%)

0.570

 

40(5.7%)

0.522

Previous MI, n (%)

79(11.2%)

333(15.5%)

0.004

 

81(11.5%)

0.837

Previous PCI, n (%)

101(14.3%)

259(12.1%)

0.124

 

80(11.4%)

0.103

Previous CABG, n (%)

3(0.4%)

18(0.8%)

0.264

 

4(0.5%)

0.725

Atrial flutter/Fibrillation, n (%)

28(4.0%)

77(3.6%)

0.648

 

26(3.7%)

0.798

Hypertension, n (%)

411(58.1%)

1334(62.1%)

0.057

 

426(60.5%)

0.347

Hypercholesteremia, n (%)

256(36.2%)

741(34.5%)

0.417

 

259(36.8%)

0.805

Diabetes, n (%)

239(33.8%)

734(34.2%)

0.846

 

233(33.1%)

0.793

Heart failure, n (%)

30(4.2%)

134(6.2%)

0.047

 

31(4.4%)

0.878

Renal insufficiency, n (%)

17(2.4%)

86(4.0%)

0.048

 

19(2.7%)

0.723

Anemia, n (%)

110(15.5%)

235(10.9%)

0.001

 

113(16.1%)

0.791

COPD, n (%)

10(1.4%)

53(2.5%)

0.098

 

17(2.4%)

0.169

History of smoking, n (%)

358(50.6%)

1001(46.6%)

0.066

 

366(52.0%)

0.593

Family history of CAD, n (%)

21(3.0%)

50(2.3%)

0.343

 

13(1.8%)

0.170

Examinations

      

 LVEF (%)

58.48 ± 7.68

57.91 ± 9.24

0.106

 

57.68 ± 8.87

0.071

 Hb (g/L)

132.11 ± 14.95

131.04 ± 17.11

0.110

 

130.48 ± 18.93

0.072

 sCr (mmol/L)

73(64,82)

71(62,84)

0.189

 

71(62,81)

0.073

 LDL-C (mmol/L)

2.07 ± 0.79

2.16 ± 0.88

0.012

 

2.14 ± 0.86

0.111

Medication use

      

 DAPT, n (%)

708(100%)

2149(100%)

1.000

 

704(100%)

1.000

 Duration of DAPT (month)

6(6,12)

12(12,12)

<0.001

 

12(12,12)

<0.001

 Statins, n (%)

692(97.7%)

2122(98.7%)

0.057

 

694(98.6%)

0.241

 Beta-Blockers, n (%)

635(89.7%)

1899(88.4%)

0.335

 

639(90.8%)

0.495

 ACEI/ARB, n (%)

216(30.5%)

638(29.7%)

0.679

 

212(30.1%)

0.872

 PCSK9i, n (%)

49(6.9%)

160(7.4%)

0.642

 

34(4.8%)

0.095

  1. Notes: DCB, Drug-coated balloon; sDES, second-generation drug-eluting stent; CAD, coronary artery disease; ACS, acute coronary syndrome; UA, unstable angina; NSTEMI, acute non-ST-elevation myocardial infarction; STEMI, acute ST-elevation myocardial infarction; SCAD, stable coronary artery disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; Hb, hemoglobin; sCr, serum creatinine; LDL -C, low-density lipoprotein cholesterol; DAPT, dual antiplatelet therapy; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; PCSK9i, the proprotein convertase subtilin Kexin-9 inhibitor; continuous variables were presented as mean ± standard deviation or median (interquartile range, IQR); categoric variables were shown as number (%)
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us